Core Insights - Ping An Health Insurance is committed to the "Healthy China" strategy, aiming to integrate health insurance with medical and health services, transitioning towards a professional medical health management company [2][3] - The company has launched the "Healthy Kitchen" standard to address unhealthy dietary habits, providing guidelines for nutrition, safety, processing, and cooking [2] - The "Forever Together" health membership card offers comprehensive health benefits, promoting a positive cycle of health rewards for members [2][3] Group 1 - The collaboration with Peking University Health Science Center aims to promote health management starting from family kitchens [2] - The launch of over 80 safe and traceable health food products in the "Healthy Kitchen" online store is part of the initiative to enhance health management at home [2] - The membership card includes nine benefits, such as dietary guidance, discounts on health products, and medical service perks, encouraging healthier lifestyles [2] Group 2 - The "Ping An Happy Health" insurance service system was upgraded last October, focusing on active living, quality medical care, digital healing, and long-term protection [3] - The membership card extends health management to preventive and ongoing care, helping clients convert healthy behaviors into "health assets" [3] - The company aims to deepen the integration of medical and insurance services, contributing to the construction of a healthy China and enhancing the well-being of the population [3]

三星医疗公告称，因全资子公司三星瑞典投标业务需要，公司近日向中国银行申请开立8.34万欧元（约 68.35万元）保函，担保期限至2030年2月28日。截至公告日，公司对其实际担保余额达2402.53万元。公 司累计对外担保总额97.54亿元，占2024年度净资产的80.73%，无逾期担保情况。该担保事项已履行必 要审批程序，风险总体可控。 ...

研究报告 Research Report 9 Feb 2026 香港医疗 Hong Kong Health Care 医药行业周报（2026.02.02-2026.02.06）：市场情绪回暖；看好基本面表现强劲的创新药产业链龙头 Healthcare Weekly (2026.02.02-2026.02.06): Market Sentiment Warms; Bullish on Leaders in Innovative Drug Chain with Strong Fundamentals [Table_yemei1] 观点聚焦 Investment Focus | [Table_Info] | | | | | --- | --- | --- | --- | | 股票名称 | 评级 | 股票名称 | 评级 | | 百济神州 | Outperform 华润医药 | | Outperform | | 京东健康 | Outperform 国药控股 | | Neutral | | 药明生物 | Outperform 映恩生物 | | Outperform | | 信达生物 | Outperform 金斯瑞生物科 ...

Core Viewpoint - The strong trend in the mainland healthcare sector from last year is expected to continue into this year, with investors considering the value of more R&D pipelines when evaluating valuations [1] Group 1: CDMO Sector - The company has a constructive outlook on CDMO enterprises due to accelerated growth, strong product cycles, limited geopolitical risks, and reasonable valuations [1] - Ratings for WuXi AppTec (02359, 603259.SH) and WuXi Biologics (02268) have been upgraded to "Buy" [1] Group 2: Biotech and Pharmaceutical Companies - A selective strategy is adopted for biotech and pharmaceutical companies, favoring those with key data releases and early data showing potential, along with actual transaction expectations [1] - Companies such as Kelun-Biotech (06990), Innovent Biologics (02696), and Hansoh Pharmaceutical (03692) are viewed positively [1] Group 3: Medical Devices Sector - The company maintains a neutral view on the medical devices sector, noting that while the industry has bottomed out, recovery will take time [1] - Recommendations include buying Angelalign Technology (06699) and Weigao Group (01066) [1] Group 4: Medical Services Sector - A relatively cautious stance is held regarding the medical services sector due to ongoing cost control measures and a weak consumer cycle [1] - The rating for Haijia Medical (06078) has been downgraded to "Neutral" [1]

"有微骨折的、有自体软骨截骨移植的，我自己也在网上查询相关的治疗方式，一直想找一种创伤小， 效果又比较好的治疗方式。"姚先生说。2026年1月。姚先生从复旦大学附属华山医院（以下简称"华山 医院"）运动医学科听到了一个令他振奋的好消息：通过"港澳药械通"政策，北大深圳医院引进了一项 微创软骨修复手术，这是目前唯一不用联合微骨折的软骨再生技术。 上海男子踝关节软骨损伤 "港澳药械通"破解难题 据悉，复旦大学附属华山医院运动医学科陈世益教授团队，是北大深圳医院通过深圳市医疗卫生"三名 工程"引进的高层次医学团队，双方自2016年开展合作以来，在运动医学的医、教、研等领域开展深度 合作。在该团队帮助下，北大深圳医院运动医学科已发展成为国家临床重点学科、深圳市运动医学质量 控制中心。经过综合考虑，姚先生决定前往深圳寻求新的治疗方式。 5分钟构建软骨再生支架 患者有望恢复运动功能 关节软骨损伤了，无需做软骨移植，就能让软骨再生？日前，依托"港澳药械通"政策支持，北京大学深 圳医院（以下简称"北大深圳医院"）成功完成深圳首批软骨再生胶原蛋白填充支架ChondroFiller liquid （简称CF）手术，为3名饱受关节 ...

2月6日，平安健康保险股份有限公司（以下简称"平安健康险"）联合北大医疗集团（以下简称"北大医 疗"）于北京举办"回归本真·重塑健康——中国家庭厨房健康营养优选标准暨'长相伴'健康会员卡发布 会"。会上，平安健康险携手健康营养领域权威专家、优选供应商及北大医疗，共同推出专业、科学的 中国家庭厨房健康营养倡议及"健康厨房"专区商城，并重磅发布集健康饮食、活力运动、医疗服务于一 体的"长相伴"健康会员卡权益体系，让日常健康真正省心、省时又省钱。 平安健康险党委书记、董事长兼CEO朱友刚表示，平安健康险坚定贯彻"健康中国"战略和金融监管总局 政策精神，此次"健康厨房"及"长相伴"会员卡的发布，是公司在推动"健康保险+医健服务"深度融合、 向"专业医疗健康管理公司"转型的又一创新实践。平安健康险将持续发挥"服务X保险"的整合资源优 势，以专业为底色，不断升级健康管理服务的模式、品质与体验，守护亿万国民的家庭健康美好生活。 首发中国家庭厨房健康营养优选标准，引领行业健康管理新范式 当今社会正面临严峻的营养现实危机，天然食物摄入不足、过度依赖加工食品、营养认知偏差等不健康 饮食习惯已成为超重肥胖、众多慢性病甚至死亡的主要 ...

Core Insights - China has officially launched the trial operation of Pengbo Hospital, making it the second country globally to have a clinically approved Boron Neutron Capture Therapy (BNCT) treatment facility, marking a significant breakthrough in advanced cancer precision radiotherapy [1][3] Group 1: Hospital Launch and Operations - Pengbo Hospital, a wholly-owned subsidiary of China Biotech Services, aims to establish an integrated diagnosis and treatment service network to promote the application of BNCT technology nationwide [1] - The hospital has formed strategic partnerships with several institutions to enhance imaging technology support, explore combined treatments, develop inclusive medical insurance, and establish a collaborative treatment network [1] Group 2: Market Potential and Demand - As the only approved BNCT clinical treatment facility in China, Pengbo Hospital is expected to become a core growth driver for the company by 2026, driven by both policy support and market demand [2][3] - The potential demand for BNCT centers in major cities across China is estimated to be no less than 700 units, indicating a vast market opportunity [3] Group 3: Treatment Efficacy and Applications - BNCT is recognized for its precision targeting, minimal side effects, and repeatability, with international clinical data showing over 80% one-year survival rates for patients with advanced or recurrent head and neck cancers [3] - The hospital's approved indications include various types of inoperable locally advanced or recurrent head and neck cancers, with ongoing clinical research expanding to other solid tumors such as breast cancer and glioblastoma [3] Group 4: Financial Outlook and Growth - The hospital's initial capacity is approximately 40 beds, with an expected annual patient reception capacity of 1,500 to 2,500, potentially generating annual revenues of 700 million to 1.2 billion yuan based on treatment costs [5] - The continuous approval of new indications is anticipated to provide new revenue growth points for the company, contributing to a transformation of its main business and a potential revaluation of the company's stock [4][5]

该股主要指标及行业内排名如下： 创新医疗融资融券信息显示，融资方面，当日融资买入9138.35万元，融资偿还1.15亿元，融资净偿还 2325.24万元。融券方面，融券卖出0.0股，融券偿还0.0股，融券余量1.37万股，融券余额37.76万元。融 资融券余额5.42亿元。 近5日融资融券数据一览见下表： 证券之星消息，截至2026年2月6日收盘，创新医疗(002173)报收于27.56元，下跌6.1%，换手率 13.49%，成交量56.14万手，成交额15.58亿元。 2月6日的资金流向数据方面，主力资金净流出1.39亿元，占总成交额8.92%，游资资金净流入469.64万 元，占总成交额0.3%，散户资金净流入1.34亿元，占总成交额8.62%。 近5日资金流向一览见下表： 创新医疗2025年三季报显示，前三季度公司主营收入5.97亿元，同比下降2.11%；归母净利润472.44万 元，同比上升116.97%；扣非净利润-2946.98万元，同比上升6.05%；其中2025年第三季度，公司单季度 主营收入1.96亿元，同比下降3.16%；单季度归母净利润1608.57万元，同比上升236.15%；单季度扣 ...

Core Viewpoint - The company is actively engaging with investors and stakeholders to discuss its product developments, market strategies, and future growth prospects, particularly in the PVP product line and high-margin offerings like Euriz. Group 1: PVP Product Insights - The prices of PVP series products are expected to gradually recover in 2026 after a period of high margins due to the European energy crisis and the Russia-Ukraine conflict, which had previously inflated raw material costs [3] - The company anticipates that PVP product sales will enter an upward trend based on market demand and supply dynamics [3] Group 2: New Energy and Photovoltaic Applications - In the new energy battery sector, PVP is utilized as a dispersant for carbon nanotubes, with sales projected to reach approximately 4,000 tons in 2025, expecting a 20% increase in 2026 [4] - In the photovoltaic sector, PVP serves as a key surfactant/dispersant for spherical silver powder, which is crucial for silver paste printing performance and battery efficiency, with 2025 shipments estimated at 200 tons and continued growth expected in 2026 [4] Group 3: Euriz Product Advantages - Euriz (ethylene-vinyl ether/maleic anhydride copolymer) is a high-value product with a high price per ton and a gross margin of approximately 60-70%, with an expected shipment volume of around 900 tons in 2025 [5] - The company is the only manufacturer globally using a non-benzene process for Euriz production, creating a significant technical barrier and is actively seeking partnerships to enhance market presence [5] Group 4: Shareholder Communication and Equity Structure - The company emphasizes effective communication with shareholders and has reached consensus with its top ten shareholders on operational and governance matters [6] - The major shareholder plans to increase their stake in the company by liquidating some personal assets, aiming to optimize the equity structure and stabilize control [6] Group 5: Medical Sector Developments - The company has invested in five cell and gene therapy enterprises, with several products progressing well in their development stages, including one product entering NDA approval and others in clinical trials [7] - Some of these enterprises are positioned to potentially achieve NDA approval and initiate IPOs, with the company collaborating closely with them for market promotion and commercialization [7] Group 6: Strategic Transformation Goals - The company is transitioning from a capacity-led approach to a focus on technology and service leadership, with plans to establish itself as a global leader in functional chemicals by 2025-2027 [8]

（来源：工人日报） 医保部门通过数据发布，把上述病种分析结果反馈给医院，在数据与专业沟通的作用下，医疗机构积极 组织临床科室对诊疗路径进行复盘与规范培训。经过半年时间改进，该医院大叶性肺炎的心电监测及血 氧饱和监测使用率从97%下降至71%，次均费用由4450元下降至4095元，降幅为8%。实现医疗机构主动 控成本、增质效的协同目标，引导医疗服务更加规范，提升了医保基金使用效率，让患者少做无用检 查，少花冤枉钱。 此外，病种专题分析还有助于发现基金使用疑似问题线索。陕西榆林在公开发布的数据中发现，某院肺 源性心脏病患者中，关键辅助诊断性项目心脏彩超的使用率仅为8.73%，核心治疗药物呋塞米的使用率 仅为7.4%，数据发布提示可能存在高套编码等疑似线索，引起医疗机构重视，有针对性地开展自查。 据介绍，作为数据发布的重要探索，病种专题分析实现了3个功能：精准呈现，通过病种分析清晰展示 医疗机构临床实践的客观差异；专业解读，结合医学逻辑与医保政策导向，剖析数据背后可能反映的行 为偏差；明确方向，为诊疗行为合理化提供参考建议，促使医疗机构主动对标、不断优化。 国家医保局有关负责人表示，将持续开展医保数据发布，推动工作 ...